Further evidence about sunitinib's neurological side effects is elucidated through a study examining the levels of the vascular endothelial growth factor/vascular permeability factor (VEGF) in the serum and cerebrospinal fluid (CSF) from 10 patients with PEOMS syndrome (syndrome of polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes) [9]. Here, MYOM2 is linked to endocrine system disorder.